News Gilead poaches oncology expert Quigley from BMS Gilead has poached an oncology research leader from Bristol-Myers Squibb, appointing Michael Quigley as senior vice president of research biology.
Views & Analysis Delivering innovative therapies with close industry-NHS part... It was a crucial moment when NHS England and the National Institute for Health and Care Excellence (NICE)
News Gilead highlights Yescarta survival data in ASCO update Gilead’s Kite subsidiary has reported new data from the main trial for its CAR-T Yescarta, hoping to encourage greater use of the slow-growing therapy. Updated results from the ZUM
News Gilead develops solid tumour cell therapy with Gadeta Gilead has option to buy biotech if things go well
News Kite expands manufacturing capacity for CAR-T therapies Less than a year after it was acquired by Gilead in a $11.9 billion deal,
News UK project addresses capacity issue in CGT manufacturing A UK consortium has been set up to tackle a major issue in the development of cell and gene therapies (CGT) – a lack of manufacturing capacity.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face